<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095016</url>
  </required_header>
  <id_info>
    <org_study_id>002-TWB-0901</org_study_id>
    <nct_id>NCT01095016</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients</brief_title>
  <official_title>An Open-label, Randomized, Cross-over, Active-controlled Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Otsuka Pharm. Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Otsuka Pharm. Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, cross-over, active-controlled study to evaluate the
      efficacy and safety effects using Meptin® Swinghaler and Berotec N® Metered Aerosol in stable
      asthma patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of Forced Expiratory Volume in 1 second (FEV1) value</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of Peak Expiratory Flow Rate (PEFR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Forced Vital Capacity (FVC)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device acceptance</measure>
    <time_frame>12 months</time_frame>
    <description>5-point score of evaluation form to test preference on Meptin swinghaler/ Berotec device by investigator or patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Meptin swinghaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Berotec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meptin swinghaler</intervention_name>
    <description>Dose: 10ug/puff, 2 puffs daily
Frequency: QD (total 20ug/day)
Treatment duration: 2 days</description>
    <arm_group_label>Meptin swinghaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berotec</intervention_name>
    <description>Dose: 100ug/puff, 2 puffs daily
Frequency: QD (total 200ug/day)
Treatment duration: 2 days</description>
    <arm_group_label>Berotec</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or females outpatients aged ≥18 years old with uncontrolled or partly controlled
             asthma; Stability was assessed during the past 14 days the patients remained in the
             same severity class by 2006 GINA guideline (uncontrolled, partly controlled) and had
             no acute exacerbations by investigator judgment;

          -  Pulmonary function test: Improvement ≥12% reversibility in FEV1 or FVC following
             administration of an inhaled β2-agonist before the study or ; Positive result of
             Brocho-provocation test;

        Exclusion Criteria:

          -  Hypersensitivity to β2-agonist or lactose;

          -  Hospitalization due to asthma during the previous 3 months;

          -  Respiratory tract infection requiring treatment with antibiotics in the previous 4
             weeks;

          -  Oral or systemic corticosteroids in the previous 4 weeks;

          -  Inadequately controlled hyperthyroidism;

          -  Subjects with any clinically significant disorder of the cardiovascular, neurologic,
             hematologic, gastrointestinal, cerebrovascular, or immunologic system or respiratory
             disease other than asthma(e.g. COPD), or any other disorder which may interfere wth
             the study evaluations or affect subject safety;

          -  Patients receive an investigational drug within 30 days prior to admission to the
             study;

          -  Patients with significant alcohol, drug or medication abuse as judged by the
             investigator;

          -  Females who are pregnant or breast-feeding; (exception: Females of child-bearing age
             might be included, if in the opinion of the investigator, they are using adequate
             contraceptive precautions);

          -  Subjects who are heavy smoker (more than 10 packs year) or who are smoking within
             previous 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Hsiu Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Cung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Cung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2010</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenoterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

